Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 07, 2025 03:30 ET | Source: Salipro Biotech AB

Salipro Biotech Strengthens Global IP Portfolio with Two New Japanese Patents

Salipro Biotech secures two new Japanese patents, strengthening its platform for stabilizing challenging membrane proteins to unlock new drug targets.
May 21, 2025 09:00 ET | Source: Synfini

Synfini Inc. and Multispan Announce Drug Discovery Collaboration

MENLO PARK, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Synfini, Inc., the leader in AI-driven agile chemistry for better molecule discovery, announced today that it has entered a collaboration with...
May 19, 2025 07:00 ET | Source: OKYO Pharma LTD

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic...
November 07, 2024 08:30 ET | Source: Vaccinex, Inc.

Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

Partnerships will employ Vaccinex’s ActivMAb® tech. Successful antibody discovery campaigns for cancer immunotherapy to be presented at SITC Nov 9, 2024.
March 20, 2024 20:01 ET | Source: Sosei Group Corporation

Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease

GPR35 is a novel target with an established genetic association to IBDUK regulatory approval received to commence first-in-human studiesReturn of rights follows change in immunology research strategy...
March 06, 2024 20:30 ET | Source: Orion Biotechnology Canada Ltd.

Orion Biotechnology Presenting at the 3rd GPCR-Targeted Drug Discovery Summit in Boston

Ottawa, Canada, March 06, 2024 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G...
February 21, 2024 08:00 ET | Source: Vaccinex, Inc.

Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology

Eight new antibody discovery agreements incorporate Vaccinex’s powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against...
February 15, 2024 18:35 ET | Source: Sosei Group Corporation

Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Office

Tokyo, Japan and Cambridge, UK, 16 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), today announces that at a meeting held on 15 February 2024, its Board of...
December 14, 2023 03:29 ET | Source: GPCR Therapeutics

GPCR Therapeutics Announces Out-Licensing Agreement with Bridge Biotherapeutics in Idiopathic Pulmonary Fibrosis

SEOUL, Korea and REDWOOD CITY, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- GPCR Therapeutics, Inc., a clinical-stage international biopharmaceutical company, announces it enters into an out-licensing...
November 10, 2023 01:35 ET | Source: Sosei Group Corporation

Sosei Heptares and Kallyope Nominate First GPCR Target for Therapeutic Development in Gastrointestinal Diseases

Tokyo, Japan, Cambridge, UK and New York, USA – 10 November 2023 – Sosei Group Corporation (“Sosei Heptares”; TSE: 4565), the international biopharmaceutical company, and Kallyope, a clinical stage...